Back to Search
MICHAEL VOGLER, M.D.
M.D.
Pediatrics Physician
NPI: 1528021524Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
PMID 19258513·Cancer Res·2009
7-preclinical
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
PMID 18829553·Cancer Res·2008
7-preclinical
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.
PMID 16832350·Oncogene·2007
8-other
Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity.
PMID 16091752·Oncogene·2005
4-observational
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
PMID 15097300·J Acquir Immune Defic Syndr·2004
3-trial
Acute MI with long-standing AIDS: a perfect storm of risk factors for premature coronary artery disease.
PMID 19554739·AIDS Read·2009
5-case
Different forms of cell death induced by putative BCL2 inhibitors.
PMID 19390557·Cell Death Differ·2009
7-preclinical
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance.
PMID 19036706·Blood·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7 ALFRED ST, BALDWIN PARK II
WOBURN, MA 01801 - Phone
- (781) 933-6236
Quick Facts
- NPI
- 1528021524
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile